February 2025, Vol 2, No 2

With the new year, our nation has seen much change, starting notably, with the swearing-in of President Donald J. Trump as the 47th President of the United States. Shortly after the President took his Oath of Office, officials with Veterans Affairs (VA) noted his newest appointments, which we’ve reported on in the pages of this publication. Many of these appointees are familiar, as they worked in similar roles during Trump’s first go-round as Commander in Chief. Read More ›

Generative artificial intelligence (AI) holds the potential to improve patient care but there are also ethical challenges that accompany its integration into healthcare. Read More ›

Initial treatment with monoclonal antibodies alone did not boost the risk for other cancers (OCs) in a group of US veterans who had been diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), but initial treatment with chemoimmunotherapy was associated with a significant increase of OCs, according to results of a recently presented study. Read More ›

Addressing modifiable risk factors for anticoagulant-related bleeding in patients with cancer is an effective way to reduce bleeding and enable these patients to continue anticoagulant therapy, according to the results of a recently presented study at the 66th ASH Annual Meeting & Exposition held in San Diego, CA. Read More ›

Later cancer treatment initiation and fewer treatment options once treatment starts are just some of the impacts of longer driving distances to treatment, according to researchers reporting in a study presented at the 66th ASH Annual Meeting & Exposition held in San Diego, CA. Read More ›

Machine learning may hold promise for analyzing cells coexpressing MYC and BCL2 but lacking BCL6 (M+2+6-) in diffuse large B-cell lymphoma (DLBCL), which can be associated with poorer survival patterns, according to a study presented at the 66th ASH Annual Meeting & Exposition held in San Diego, CA. Read More ›

In patients with newly diagnosed multiple myeloma (NDMM), the use of anti-CD38 monoclonal antibodies (mAbs) enhances the effectiveness of standard treatment protocols, according to a study presented at the 66th ASH Annual Meeting & Exposition in San Diego, CA. Read More ›

A prevalence of 6-fold higher-than-average reported in the National Health and Nutrition Examination Survey Study of light-chain (LC) monoclonal gammopathy of undetermined significance (MGUS) has been shown in US service members (SMs), but does not appear to be linked to burn pit exposure, according to a study presented at the 66th ASH Annual Meeting & Exposition held in San Diego, CA. Read More ›

Officials with Vertex Pharmaceuticals Incorporated announced that the FDA has approved suzetrigine (Journavx), a first-in-class, oral, nonopioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. Read More ›

Axsome Therapeutics, Inc., a biopharmaceutical company, has announced that the FDA has approved meloxicam and rizatriptan (Symbravo) for the acute treatment of migraine with or without aura in adults. Read More ›